Stay Ahead of Wall Street. Find out what is happening to Nektar Therapeutics (NASDAQ:NKTR) stock today? Its price is nose-diving 0 points, trading at $33.9 levels, and is down 0% from its previous close of $33.9. The shares seem to have an active trading volume day with a reported 0 contracts so far this session. NKTR shares had a relatively better volume day versus average trading capacity of 1.66 million shares, but with a 0.17 billion float and a 2.79% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for NKTR stock indicates that the average analyst price target is $70.82 per share. This means the stock has a potential increase of 108.91% from where the NKTR share price has been trading recently which is between $33.06 and $34.62. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $37.
The shorts are running away from Nektar Therapeutics (NKTR) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a drop in short interest in NKTR shares. While short interest still represents only 10.29% of NKTR’s float, the number of shares shorted have fallen by -43952. The number of shares shorted fell to 17726962 shares, down from 17770914 shares during the preceding fortnight. With average daily trading volumes at 1816035 shares, days to cover decreased to about 14.84017 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology’s (ASCO) Annual Meeting” and dated May 15, 2019.
During the recent trading session for Nektar Therapeutics (NASDAQ:NKTR), the company witnessed their stock drop by $-3.05 over a week and surge $1.21 from the price 20 days ago. When compared to their established 52-week high of $92.17, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 01/06/18. The recent low of $29.22 stood for a -63.22% since 12/24/18, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.87 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Nektar Therapeutics, the two-week RSI stands at 52.75. This figure suggests that NKTR stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current NKTR readings is similarly very revealing as it has a stochastic reading of 48.94% at this stage. This figure means that NKTR share price today is being neutral.
Technical chart claims that Nektar Therapeutics (NKTR) would settle between $34.66/share to $35.42/share level. However, if the stock price goes below the $33.1 mark, then the market for Nektar Therapeutics becomes much weaker. If that happens, the stock price might even plunge as low as $32.3 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.06. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at SVB Leerink, assumed coverage of NKTR assigning Mkt Perform rating, according to their opinion released on March 15. Goldman, analysts launched coverage of Nektar Therapeutics (NASDAQ:NKTR) stock with a Buy recommendation, according to their flash note issued to investors on December 13. Analysts at H.C. Wainwright lowered the stock to a Neutral call from its previous Buy recommendation, in a research note that dated back to June 11.
NKTR equity has an average rating of 1.92, with the figure leaning towards a bullish end. 13 analysts who tracked the company were contacted by Reuters. Amongst them, 3 rated the stock as a hold while the remaining 10 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 10 analysts rated Nektar Therapeutics (NASDAQ:NKTR) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, NKTR stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 29.14 while for the average stock in the same group, the multiple is 49.5.
Nektar Therapeutics (NKTR)’s current-quarter revenues are projected to climb by nearly -97.61% to hit $25.96 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over -91% from $1.19 billion to a noteworthy $107460. At the other end of the current quarter income statement, Nektar Therapeutics is expected to see its adjusted earnings surge by roughly -115.01% to hit $-0.8 per share. For the fiscal year, NKTR’s earnings are projected to climb by roughly -183.07% to hit $-3.14 per share.